Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Flolan to Veletri in PAH
NCT01431716Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Mar 2011
- Primary completion
- Feb 2012
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of epoprostenol in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Pulmonary Vascular Resistance at 3 months, Total Pulmonary Resistance at 3 months and 4 more. Started Mar 2011; status: completed.
02
Drugs
epoprostenol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01431716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01431716.